Introduction {#s1}
============

Women who present with acute coronary syndrome (ACS) are typically older than men, and have a higher frequency of concomitant hypertension or diabetes mellitus, and less often a history of myocardial infarction (MI).^[@EHU075C1]--[@EHU075C12]^ Studies suggest that the treatment and approach of ACS also differs between women and men, including the use of effective short-term medication (as thrombolytics), long-term medication, do-not-resuscitate orders, and invasive procedures.^[@EHU075C1],[@EHU075C3],[@EHU075C5]--[@EHU075C9],[@EHU075C13]^

A number of reports indicated no significant differences between sexes for in-hospital or 30-day mortality, after adjustment for baseline characteristics.^[@EHU075C4]--[@EHU075C6],[@EHU075C8]--[@EHU075C11],[@EHU075C14]^ Also regarding long-term mortality rates, adjusted data in several reports suggest no difference between the sexes.^[@EHU075C1],[@EHU075C2],[@EHU075C6],[@EHU075C9]^ However, the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) study reported lower all-cause mortality in women at 1 year, after adjustment for age.^[@EHU075C10]^

Ticagrelor is a reversibly binding, oral P2Y~12~ receptor antagonist.^[@EHU075C15]^ It has been approved in \>90 countries for preventing thrombotic events in patients with ACS.^[@EHU075C16],[@EHU075C17]^ In the phase III PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor significantly reduced the composite rate of death from cardiovascular causes (CV death), MI, or stroke at 12 months, without increasing the rate of PLATO-defined overall major bleeding, compared with clopidogrel in patients with ACS with or without ST-segment elevation.^[@EHU075C18]^

Given the potential importance of sex on treatment approach and outcome in patients with ACS, we present a pre-specified analysis of the association between sex and the effects of ticagrelor vs. clopidogrel on clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation ACS in the PLATO trial.

Methods {#s2}
=======

Summary of PLATO methodology {#s2a}
----------------------------

PLATO was an international, multicentre, randomized, double-blind trial. The methodology of PLATO (including study design, inclusion and exclusion criteria, patients and outcome variables) has been published previously.^[@EHU075C18],[@EHU075C19]^ In brief, 18 624 patients hospitalized for ACS, with or without ST segment elevation, were randomized to receive ticagrelor or clopidogrel in a double-blind, double-dummy manner within 24 h of the most recent cardiac ischaemic symptoms and before any planned or urgent percutaneous coronary intervention (PCI).

Ticagrelor was administered as a loading dose of 180 mg followed by 90 mg twice daily. Clopidogrel was administered as a maintenance dose of 75 mg daily, preceded by a loading dose of 300 mg in patients who had not received an open-label loading dose and had not received clopidogrel for ≥5 days before randomization. Before PCI procedures, a further 300 mg clopidogrel dose (or ticagrelor 90 mg in the case of PCI procedures later than 24 h after randomization) was permitted at the discretion of the investigator. The assigned study treatment was continued for at least 6 months and up to a maximum of 12 months. All the patients also received acetylsalicylic acid (aspirin) 75--100 mg/day unless they were known to be aspirin intolerant. For patients who previously had not received aspirin, the preferred loading dose was a maximum of 325 mg. After stent placement, an aspirin dose of up to 325 mg/day for 6 months was permitted.

The primary efficacy endpoint was the composite of time to first occurrence of MI, stroke, or CV death, and the primary safety endpoint was time to PLATO-defined and adjudicated first major bleeding event.^[@EHU075C19]^

The study adhered fully to the ethical principles of the Declaration of Helsinki, the research protocol was approved by all appropriate locally appointed ethics committees, and informed consent was obtained from the patients.^[@EHU075C18],[@EHU075C19]^

Statistical analysis {#s2b}
--------------------

Patient characteristics were compared according to sex using χ^2^ and Wilcoxon rank-sum tests. Cox proportional-hazards models were used to analyse the association between sex subgroup and the primary composite endpoint and each of the secondary endpoints and major bleeding endpoints.

Adjustment variables besides geographic region also included age, weight, height, body mass index, waist circumference, heart rate, systolic blood pressure, smoking status, white blood cell count, haemoglobin level, creatinine clearance, troponin level, time from onset of symptoms to randomization, changes in electrocardiogram (ECG) at entry (ST-elevation or ST-depression), Killip class at entry, glycoprotein inhibitors (GPIs) at entry, prior MI, prior stroke, prior transient ischaemic attack (TIA), prior PCI, prior coronary artery bypass grafting (CABG), prior gastrointestinal bleeding episodes, diabetes, peripheral arterial disease (PAD), dyslipidaemia, angina pectoris, congestive heart failure, final diagnosis, randomized treatment, and treatment approach.

The interaction of sex subgroup with treatment effects was investigated by use of Cox proportional-hazards models. For efficacy endpoints, all analyses were based on the intent-to-treat approach. Bleeding endpoints were analysed up to 7 days after permanent discontinuation, and only in patients who had received at least one dose of the study drug. Dyspnoea rates by gender and randomized treatment at 1 year were estimated using the Kaplan--Meier (KM) method. Hazard ratios (HR) comparing the randomized treatments and the treatment by gender interaction test were derived using a Cox regression model.

The proportional hazard assumption was assessed using the method proposed by Lin *et al*.^[@EHU075C20]^ based on the cumulative sum of martingale residuals. For the endpoints where the proportional hazard assumption was not met, a piecewise proportional hazard model was used. The cutpoints for the piecewise segments were selected using likelihood ratio tests.

Ventricular pauses by gender and treatment at first week and 30 days were summarized as percentages. Odds ratios comparing randomized treatments and the treatment by gender interaction were derived using a logistic regression model.

All the analyses were performed using SAS^®^, version 9.2 (SAS Institute, Gary, NC, USA). Comparisons for exploratory analyses used a two-sided significance level of 0.05 without correction for multiple comparisons.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

Baseline characteristics of the study population are presented in *Table [1](#EHU075TB1){ref-type="table"},* stratified by sex. Fewer women than men were randomized in the PLATO trial, with the study population comprising 28.4% women (5288/18 624); percentage of women was approximately uniform across regions (data not shown). There was no significant difference in the allocation of randomized treatments between sexes. Baseline characteristics of women randomized to the two arms of the study are presented in [Supplementary material online, *Table S1B*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu075/-/DC1). Table 1Patient baseline characteristics, final diagnosis, and managementCharacteristicWomen (*n* = 5288)Men (*n* = 13 336)*P*-valueWeight and BMI Median body weight, kg (25th--75th percentile)71 (62--81)82 (73--92)\<0.0001 Body weight \<60 kg, % (*n*)16.7 (878)3.3 (434)\<0.0001 Median BMI, kg/m^2^ (25th--75th percentile)27.5 (24.4--31.1)27.4 (24.8--30.2)0.1040Age ≥75 years23.7 (1251)12.2 (1627)\<0.0001Habitual smoker23.1 (1221)41.0 (5457)\<0.0001Hypertension76.8 (4058)61.0 (8125)\<0.0001Dyslipidaemia, including hypercholesterolaemia48.2 (2547)46.1 (6142)0.0090Angina pectoris48.6 (2568)43.4 (5790)\<0.0001Myocardial infarction17.8 (940)21.6 (2884)\<0.0001Congestive heart failure8.2 (431)4.6 (619)\<0.0001PCI10.9 (575)14.4 (1917)\<0.0001CABG4.2 (221)6.6 (885)\<0.0001TIA3.2 (169)2.5 (330)0.0059Non-haemorrhagic stroke4.6 (243)3.6 (479)0.0014PAD5.4 (287)6.4 (857)0.0106Chronic renal disease4.7 (247)4.0 (538)0.0508Baseline laboratory values, median (25th--75th percentile) Glucose, mmol/L7.0 (5.8--9.2)6.8 (5.7--8.7)\<0.0001 HbA~1c~, %6.1 (5.7--6.9)5.9 (5.6--6.5)\<0.0001 EGFR, mL/min/1.73 m^2^74 (59--89)86 (71--01)\<0.0001Final diagnosis, % (*n*) STEMI30.6 (1613)40.7 (5413)\<0.0001 NSTEMI43.0 (2266)42.8 (5689) Unstable angina22.8 (1202)14.3 (1910) Other3.6 (192)2.2 (297)Pre-randomization management strategy Planned invasive, % (*n*)64.0 (3382)75.2 (10 026)\<0.0001 Randomized to ticagrelor, % (*n*)50.2 (2655)50.1 (6678)0.8699Procedures during study PCI before discharge51.0 (2698)65.0 (8665)\<0.0001 PCI during study54.1 (2859)68.4 (9119)\<0.0001 Coronary angiography before discharge74.4 (3935)84.3 (11 235)\<0.0001 Coronary angiography during study79.2 (4187)88.4 (11 793)\<0.0001 CABG before discharge4.0 (211)5.7 (759)\<0.0001 CABG during study7.8 (411)11.2 (1488)\<0.0001Concomitant medication taken during study, % (*n*) Aspirin95.8 (5062)96.5 (12 852)0.0317 β-Blockers85.3 (4505)85.5 (11 390)0.6918 ACE and/or angiotensin II inhibitors87.1 (4598)85.3 (11 363)0.0022 Statins91.6 (4838)94.8 (12 622)\<0.0001 Calcium channel inhibitors29.6 (1565)21.7 (2893)\<0.0001 Diuretics49.4 (2607)38.3 (5100)\<0.0001[^1][^2]

In terms of CV risk factors, age ≥75 years, dyslipidaemia, and hypertension were more frequent in women compared with men, whereas men more frequently reported habitual smoking. More women had a previous history of angina pectoris, chronic heart failure, TIA or non-haemorrhagic stroke, and more men had previously had manifestations of PAD, MI, PCI, or CABG. Median serum glucose and glycosylated haemoglobin (HbA~1c~) levels were higher in women than in men. The median estimated glomerular filtration rate was higher in men. Following study entry, women more frequently had a final diagnosis of unstable angina than men, but had fewer final diagnoses of ST-elevation myocardial infarction (STEMI). Planned and received procedures, including CABG, were more frequent in men.

Association between sex and outcomes, independent of randomized treatment {#s3b}
-------------------------------------------------------------------------

In the overall population, female sex was not significantly associated with the risk of the primary composite endpoint \[adjusted HR: 1.02 (0.91−1.16); *Figure [1](#EHU075F1){ref-type="fig"}*\]. Female sex was also not significantly associated with all-cause death \[adjusted HR: 0.86 (0.73−1.02)\], incidence of stent thrombosis \[adjusted HR: 0.81 (0.56−1.18)\], or other efficacy endpoints. Unadjusted data for efficacy endpoints in females and males are described in [Supplementary material online, *Table S2A*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu075/-/DC1). Figure 1Association between sex and clinical outcome. \**n* = 5288. ^†^*n* = 13 336. ^‡^Adjustment variables selected from the following: age, weight, height, body mass index, waist circumference, race, smoking status, diabetes, hypertension, heart rate, systolic blood pressure, changes in electrocardiogram at entry, electrocardiogram depression, killip class at entry, age, haemoglobin, white blood cells, dyslipidaemia, creatinine, angina pectoris, prior myocardial infarction, congestive heart failure, prior GI bleeding, prior percutaneous coronary intervention, prior coronary artery bypass grafting, prior transient ischaemic attack, prior non-haemorrhagic stroke, peripheral arterial disease, renal disease, chronic obstructive pulmonary disease, final diagnosis, onset of symptoms to randomized treatment, glycoprotein IIb/IIIa inhibitors at randomization, randomized treatment, treatment approach, and region. ^§^PLATO-defined and adjudicated^[@EHU075C19]^. ^††^Any bleeding includes major, minor, and minimal bleedings. CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV death, death from cardiovascular causes; ECG, electrocardiogram; GI, gastrointestinal bleeding; HR, hazard ratio; KM, Kaplan--Meier analysis; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TIA, transient ischaemic stroke.

Regarding safety endpoints, rates of non-CABG-related major bleeding did not differ significantly between sexes \[adjusted HR: 1.16 (0.96−1.40)\], but women experienced a lower rate of CABG-related major bleeding events \[adjusted HR: 0.57 (0.49−0.67)\]. PLATO-defined and adjudicated overall major bleeding rate was lower in women than in men \[adjusted HR: 0.81 (0.71−0.92)\], but this difference may be explained by the lower CABG-related bleeding rate and less use of CABG in women. When major and minor bleeding were combined, there was still significantly less bleeding in women compared with men (*Figure [1](#EHU075F1){ref-type="fig"}*). The same was true for any bleeding including major, minor, and minimal bleeding (*Figure [1](#EHU075F1){ref-type="fig"}*). Age and body mass index were univariately associated with major bleeding but the association of body mass index disappeared when adjusted by age. Women were more likely to have low body mass index than men (data not shown). Unadjusted data describing the association of gender with endpoints are provided in [Supplementary material online, *Table S2A*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu075/-/DC1).

Association between sex and efficacy of randomized treatment {#s3c}
------------------------------------------------------------

When the association of sex with outcomes was assessed by randomized treatment, ticagrelor was associated with similar reductions among women and men in CV death, MI, or stroke \[women: adjusted HR: 0.88 (0.74--1.06); men: adjusted HR: 0.86 (0.76--0.97); *Figures [2](#EHU075F2){ref-type="fig"}* and *[3](#EHU075F3){ref-type="fig"}*\]; all-cause death \[women: adjusted HR: 0.90 (0.69--1.16); men: adjusted HR: 0.80 (0.67--0.96) *Figures [2](#EHU075F2){ref-type="fig"}* and *[4](#EHU075F4){ref-type="fig"}*\]; and definite stent thrombosis \[women: adjusted HR: 0.71 (0.36--1.38); men: adjusted HR: 0.63 (0.45--0.89)\] compared with clopidogrel. For these outcomes, the interaction between randomized treatment and sex remained non-significant (interaction range *P* = 0.49−0.78). [Supplementary material online, *Table S3A*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu075/-/DC1) presents unadjusted data. Figure 2Association between sex and treatment, and clinical outcome. \*Tic = ticagrelor (*n* = 9333). ^†^Clop = clopidogrel (*n* = 9291). ^‡^Adjustment variables selected from the following: age, weight, waist circumference, smoking status, diabetes, hypertension, heart rate, systolic blood pressure, changes in electrocardiogram at entry, killip class at entry, haemoglobin, white blood cells, dyslipidaemia, angina pectoris, prior myocardial infarction, congestive heart failure, prior GI bleeding, prior percutaneous coronary intervention, prior coronary artery bypass grafting, prior transient ischaemic attack, non-haemorrhagic stroke, peripheral arterial disease, chronic renal disease, chronic obstructive pulmonary disease, final diagnosis, onset of symptoms to randomized treatment, GP Iib/IIIa inhibitors at randomization, randomized treatment, treatment approach, and region. ^§^PLATO-defined and adjudicated^[@EHU075C19]^. ^††^Any bleeding includes major, minor, and minimal bleedings. CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV death, death from cardiovascular causes; ECG, electrocardiogram; GI, gastrointestinal bleeding; HR, hazard ratio; KM, Kaplan--Meier analysis; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischaemic stroke. Figure 3Cumulative Kaplan--Meier estimates of the incidence of the primary composite outcome---cardiovascular death/myocardial infarction/stroke, by sex and treatment (ticagrelor vs. clopidogrel). Estimated event rate at 12 months, ticagrelor vs. clopidogrel, interaction *P* = 0.88. CV death, death from cardiovascular causes; MI, myocardial infarction. Figure 4Cumulative Kaplan--Meier estimates of incidence of all-cause death, by sex and treatment (ticagrelor vs. clopidogrel). Estimated event rate at 12 months ticagrelor vs. clopidogrel, interaction *P* = 0.50.

Further analyses of the associations between sex, randomized treatment, and either final diagnosis (STEMI vs. NSTEMI, unstable angina or 'other') or planned treatment (invasive vs. medically managed) revealed no significant interactions for studied endpoints (interaction *P*-value range 0.20−0.83).

Association between sex and safety of randomized treatment {#s3d}
----------------------------------------------------------

There were no differences between ticagrelor and clopidogrel for PLATO-defined overall major bleeding episodes either in women \[adjusted HR: 1.01 (0.83−1.23)\] or men \[adjusted HR: 1.10 (0.98−1.24); *Figures [2](#EHU075F2){ref-type="fig"}* and *[5](#EHU075F5){ref-type="fig"}*\]. There was no evidence of randomized treatment by sex interaction for this outcome (*P* = 0.43) Unadjusted data are presented in [Supplementary material online, *Table S3B*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu075/-/DC1). No differences in major or minor bleeding, as well as any bleeding (a composite of major, minor, and minimal bleeding), were observed among women and men treated with either ticagrelor or clopidogrel (*Figure [2](#EHU075F2){ref-type="fig"}*). Figure 5Cumulative Kaplan--Meier estimates of incidence of overall major bleeding complications (PLATO-defined), by sex and treatment (ticagrelor vs. clopidogrel). Estimated event rate at 12 months ticagrelor vs. clopidogrel, interaction *P* = 0.43. CABG, coronary artery bypass.

Consistent with the main study data, ticagrelor was associated with an increase in non-CABG-related major bleeding when compared with clopidogrel in both women \[adjusted HR: 1.19 (0.90−1.56)\] and men \[adjusted HR: 1.37 (1.10−1.72); *Figure [2](#EHU075F2){ref-type="fig"}*\]. There was no significant interaction between treatment and sex (*P* = 0.42; *Figure [2](#EHU075F2){ref-type="fig"}*).

Additional analyses of the associations between sex, randomized treatment, and either final diagnosis or planned treatment also revealed no significant interactions for the bleeding endpoints (interaction *P*-value range: 0.17−0.67).

Higher rates of dyspnoea were reported during ticagrelor treatment than with clopidogrel treatment in both women \[16.3 vs. 9.0%; HR: 1.86 (1.58−2.20)\] and men \[KM estimate at 1 year: 14.2 vs. 8.3%; HR: 1.81 (1.62−2.01); *Table [2](#EHU075TB2){ref-type="table"}*\]. Ventricular pauses were more frequent in patients receiving ticagrelor compared with those receiving clopidogrel; however, a significant difference in rates was only observed for pauses of ≥3 s during the first week in men \[6.0 vs. 3.7%; HR: 1.64 (1.09−2.47)\]. There was no evidence of interaction between randomized treatment and sex for dyspnoea and ventricular pauses (interaction *P*-value range: 0.34−0.89).Table 2The incidence of dyspnoea and ventricular pauses by sex and treatmentTicagrelorClopidogrelInteraction\
*P*-valueDyspnoeaKM % (*n*)KM % (*n*)HR (95% CI)Women16.3 (389)9.0 (214)1.86 (1.58--2.20)0.7610Men14.2 (870)8.3 (500)1.81 (1.62--2.01)Ventricular pauses% (*n/N*)% (*n/N*)OR (95% CI)First week* *≥3 s  Women5.2 (20/386)3.4 (13/381)1.55 (0.76--3.16)0.8860  Men6.0 (64/1075)3.7 (39/1051)1.64 (1.09--2.47) ≥5 s  Women1.3 (5/386)1.3 (5/381)0.99 (0.28--3.44)0.3408  Men2.2 (24/1075)1.1 (12/1051)1.98 (0.98--3.97)At 30 days ≥3 s  Women1.2 (3/249)1.1 (3/265)1.07 (0.21--5.33)0.8241  Men2.4 (18/743)1.9 (14/747)1.30 (0.64--2.63) ≥5 s  Women0.4 (1/249)0.4 (1/265)1.07 (0.07--17.1)0.8541  Men0.9 (7/743)0.7 (5/747)1.41 (0.45--4.47)[^3]

Discussion {#s4}
==========

The results of the present adjusted analysis largely correspond with those reported for the large registry studies, in that men and women with ACS encounter similar mortality.^[@EHU075C1],[@EHU075C2],[@EHU075C6],[@EHU075C9]^

In the present study, unadjusted data showed a significantly higher incidence of the efficacy endpoints of CV death, myocardial infarction, or stroke (individually and in combination) in women; however, this difference disappeared after adjustment for baseline characteristics including age.

Women with ACS have been reported to have a higher risk of bleeding complications than men.^[@EHU075C21]^ The suggested important risk factors for bleeds have included a smaller body and vessel size, older age, reduced creatinine clearance, higher prevalence of comorbidities, higher rate of overdosed antithrombotic medication, and differences in response to antithrombotics between women and men.^[@EHU075C21]^ In the present study, unadjusted data showed no differences in bleeding risk between men and women. However, after adjustment for various baseline characteristics, including age, women had significantly fewer major, major or minor, and any bleeding events.

In the present analysis, the rate of overall major bleeding events appeared lower in women than men contrary to previous evidence.^[@EHU075C21]--[@EHU075C23]^ However, it is likely that this observation mainly reflects the significantly lesser use of CABG surgery and the lower rate of CABG-related major bleeding in women in the PLATO trial. Thus the non-CABG-related bleeding rates in the present study were not different between women when compared with men. This difference from the previously reported figures may be due to the careful registration of and adjustment for differences in baseline characteristics.

This analysis of the effect of female sex on outcomes related to treatment with ticagrelor and clopidogrel in ACS patients reveals results that are consistent with those reported for the primary study outcomes.^[@EHU075C18]^ This is true for both unadjusted and adjusted data. Both in women and men with ACS, ticagrelor reduced the rates of adverse CV events and mortality compared with clopidogrel, without an increase in the rate of PLATO-defined overall bleeding. In both sexes, however, and in agreement with the main study results, there was a similar increase in the rate of non-CABG-related major bleeding complications in the ticagrelor-treated patients. This finding was consistent for both unadjusted and adjusted data.

With regard to other phase III studies, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38) study reported similar efficacy for prasugrel in men (risk reduction in CV death, non-fatal MI, or non-fatal stroke = 21%) and the overall study population (risk reduction = 19%).^[@EHU075C24]^ In the TRITON-TIMI 38 study, 26% of the patients were women and compared with men they were older, lighter in body weight, more often had diabetes mellitus, hypertension, and renal impairment, but less often had prior MI and tobacco use.^[@EHU075C25]^ Rate of CV death was higher for women than men (2.9 vs. 2.0%; *P* = 0.01), but the difference disappeared after adjustment for baseline differences that included age \[HR: 1.08 (0.80--1.46)\]. Non-CABG TIMI major bleeding events occurred more frequently in women than in men, but after adjustment the difference disappeared \[HR: 1.20 (0.90--1.61)\]. However, the incidence of non-CABG TIMI minor bleeding was significantly higher in women before and after adjustment \[HR: 2.15 (1.66--2.80)\]. Sex and management with prasugrel and clopidogrel did not interact for CV death and major bleeding complications.

A numerically lower absolute reduction in efficacy endpoints was reported for women receiving clopidogrel in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study, but the difference was not significant.^[@EHU075C26]^ A meta-analysis of blinded randomized trials comparing clopidogrel and placebo (including CURE, CREDO, CLARITY-TIMI 28, COMMIT, and CHARISMA) reported no significant difference in treatment effect between men and women.^[@EHU075C27]^

A meta-analysis on early invasive therapy vs. conservative treatment strategies in women and men with non-ST-elevation ACS (NSTE-ACS) demonstrated a comparable benefit of invasive therapy in men and high-risk women, with positive cardiac biomarkers without benefits in the low-risk women.^[@EHU075C28]^ Similarly, the benefit of GPI in women with NSTE-ACS in contrast to men was restricted to the patients with a positive troponin concentration.^[@EHU075C29]^

In a separate pre-planned analysis of PLATO data, the effect and treatment-related complications of ticagrelor vs. clopidogrel in patients aged ≥75 years were compared with those aged \<75 years.^[@EHU075C30]^ The clinical benefit of ticagrelor over clopidogrel (with regard to the primary composite endpoint, definite stent thrombosis, or all-cause death), or PLATO-defined overall major bleeds, did not differ significantly between the age groups after adjustment of data for important differences in baseline characteristics including sex.

Study limitations {#s5}
=================

In the present study, comparisons were not corrected for multiplicity of analyses. The analyses were therefore susceptible to an increased type I error and subsequent increase in the likelihood of false-positive statistical differences. The study was not powered to show gender differences in efficacy and safety, but with a study population of 18 624 patients, including 5288 (28.4%) women, the total number of adjudicated events in both men and women were high, with a suitable power to show a possible sex-related heterogeneity in observed event rates.

Conclusion {#s6}
==========

In aspirin-treated patients with either STEMI managed with primary PCI, or NSTE-ACS, there were no differences between women and men for adverse clinical outcomes or concerning efficacy or safety outcomes of treatment with ticagrelor compared with clopidogrel.
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[^1]: χ^2^ and Wilcoxon rank-sum tests were used for comparisons between sexes. No adjustments were made for multiple testing.

[^2]: ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; EGFR, estimated glomerular filtration rate; HbA~1c~, glycosylated haemoglobin; NSTEMI, non-ST-elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack

[^3]: CI, confidence interval; HR, hazard ratio; KM, Kaplan--Meier analysis; OR, odds ratio.
